Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Insulet Corporation    PODD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Insulet Corporation : Insulet Announces Commercial Agreement With Amgen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2013 | 10:10pm CEST

BEDFORD, MA -- (Marketwired) -- 12/10/13 -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc., the world's leading independent biotechnology company, for a five year commercial agreement to supply Amgen with a delivery device specifically designed around the unique delivery needs of biotechnology medicines.

"We are thrilled to advance our collaboration with Amgen to supply this version of our technology," said Duane DeSisto, President and Chief Executive Officer of Insulet.

DeSisto added that "Insulet's current device, the OmniPod®, is a unique drug delivery platform that provides the ability to vary rate at which medication is infused. With over 25 million OmniPods produced, our innovative product is the undisputed global leader in patch pump technology and provides a patient-friendly and cost effective drug delivery alternative."

About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor for diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Bedford, Mass. For more information, please visit: http://www.myomnipod.com.

Forward-Looking Statement

This press release contains forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future, including those related to its arrangements with Amgen. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on the OmniPod System; Insulet's ability to increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform legislation; risks related to the implementation of a national mail-order competitive bid program; Insulet's inability to raise additional funds in the future on acceptable terms or at all; potential supply problems or price fluctuations with sole source or other third-party suppliers on which Insulet is dependent; failure by Insulet to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Insulet to retain key supplier and payor partners; international business risks; Insulet's inability to obtain adequate coverage or reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod System; failure to retain key partner payors and their members; failure to retain and manage successfully Insulet'sMedicare and Medicaid business; potential adverse effects resulting from competition with competitors; technological innovations adversely affecting the Company's business; potential termination of Insulet's license to incorporate a blood glucose meter into the OmniPod System; Insulet's ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that Insulet's current or future products infringe the proprietary rights of others; adverse regulatory or legal actions relating to the OmniPod System; failure of Insulet's contract manufacturers or component suppliers to comply with FDA's quality system regulations, the potential violation of federal or state laws prohibiting "kickbacks" or protecting patient health information, or any challenges to or investigations into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet; reduced retention rates; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulet's competitors; potential future publication of articles or announcement of positions by physician associations or other organizations that are unfavorable to Insulet's products; the expansion, or attempted expansion, into foreign markets; the concentration of substantially all of Insulet's manufacturing capacity at a single location in China and substantially all of Insulet's inventory at a single location in Massachusetts; Insulet's ability to attract and retain key personnel; Insulet's ability to manage its growth; failure to integrate successfully the Neighborhood Diabetes business; intense competition among distributors of diabetes supplies impairing Neighborhood Diabetes' business; loss by Neighborhood Diabetes of an opportunity to sell insulin pumps supplied by Insulet's competitors; failure by Neighborhood Diabetes to retain key supplier and payor partners; failure by Neighborhood Diabetes to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Neighborhood Diabetes to retain and manage successfully its Medicare and Medicaid business; existence of unanticipated liabilities arising in connection with the Neighborhood Diabetes business; fluctuations in quarterly results of operations; risks associated with potential future acquisitions; Insulet's ability to generate sufficient cash to service all of its indebtedness; the expansion of Insulet's distribution network; Insulet's ability to successfully maintain effective internal controls; the volatility of Insulet's common stock; risks related to future sales of its common stock or the conversion of the 3.75% Convertible Notes due June 15, 2016; potential limitations on Insulet's ability to use its net operating loss carryforwards; anti-takeover provisions in its organizational documents; and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2013 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

Contact:
Stephanie Marks for Insulet Corporation
[email protected]
877-PODD-IR1 (877-763-3471)

Source: Insulet Corporation

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INSULET CORPORATION
06/21 INSULET : Medical Supplies Stocks on Investors' Radar -- Endologix, Microbot Med..
06/15 INSULET : Ascensia Diabetes Care Announces Strategic Alliance with Insulet Corpo..
06/15 INSULET CORPORATION : to Present at Upcoming Investor Conference
06/12 INSULET : Presents Positive Omnipod® Horizon™ Hybrid Closed-Loop Study Res..
06/09 INSULET : to Preview New Clinical Data and Next Generation Omnipod® System at th..
06/08 ASCENSIA DIABETES CARE : Announces Strategic Alliance with Insulet Corporation t..
06/07 VALERITAS : Appoints Peter J. Devlin to Chairman of its Board of Directors
06/05 INSULET CORPORATION : to Present at Upcoming Investor Conference
06/01 INSULET CORPORATION : Ranked #4 on Forbes 2017 Most Innovative Growth Companies ..
05/30 INSULET : Appoints Bret Christensen as Chief Commercial Officer
More news
Sector news : Medical Prosthetics
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Prosthetics
News from SeekingAlpha
06/14 Insulet (PODD) Presents At The William Blair 2017 Growth Stock Conference - S..
06/09 WEAR ETF (WEAR) May Summary
05/30 Dexcom's Implantable Blood Sugar Monitor Sales Rise
05/30 New commercial chief at Insulet
05/10 Premarket analyst action - healthcare
Advertisement
Financials ($)
Sales 2017 436 M
EBIT 2017 -8,76 M
Net income 2017 -27,2 M
Debt 2017 174 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 6,88x
EV / Sales 2018 5,99x
Capitalization 2 826 M
More Financials
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | PODD | US45784P1012 | 4-Traders
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 47,5 $
Spread / Average Target -2,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. Sullivan Chairman & Chief Executive Officer
Shacey Petrovic President & Chief Operating Officer
Michael L. Levitz Treasurer, Chief Financial & Accounting Officer
Michael P. Spears SVP-Quality, Regulatory & Clinical Affairs
Aiman Abdel-Malek Senior VP-Advanced Technology & Engineering
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INSULET CORPORATION31.05%2 826
SONOVA HOLDING33.71%11 121
STRAUMANN HOLDING43.27%9 316
COCHLEAR LIMITED28.72%6 842
MODERN DENTAL GROUP LT..7.61%398
REWALK ROBOTICS LTD-14.29%30
More Results